https://www.selleckchem.com/pr....oducts/exarafenib.ht
5 months vs. 6.5 months P=0.014) and overall survival (OS) (18.5 months vs. 13.0 months, P=0.025) were longer in DEB-TACE group compared to cTACE group. Moreover, DEB-TACE (vs. cTACE) independently correlated with prolonged PFS (P=0.021) and OS (P=0.017) after adjustment by multivariate Cox's regression. Besides, most of liver function indexes were similar before and after treatment between these two groups. Also, the commonly observed adverse events were pain, fever, nausea/vomiting and blood pressure elevation with similar incidenc
Like
Comment
Share
